We are one step closer to a cure.
What is our solution?
The Usher III Initiative is developing BF844, a small molecule chaperone, for the treatment of USH3A due to the N48K mutation in the CLRN1 gene. BF844 works by stopping a protein called HSP60 from breaking down a protein called Clarin-1, which is important for vision and hearing. The next step is to test BF844 in clinical trials with healthy volunteers.
BF844 may also have the potential to treat other similar diseases.
We have come so far.
BF844 Patents
BF844 U.S. PATENTS
U.S. Patent No. 10,307,422 (pharmaceutical compositions)
U.S. Patent No. 9,925,187 (therapeutic methods)
U.S. Patent No. 9,079,909 (compositions of matter)
BF844 FOREIGN PATENTS
Australian Patent No. 201249801
Canadian Patent No. 2,834,049
European Patent No. EP2701510
Hong Kong Patent No. HK1195507
Israeli Patent No. 229023
Japanese Patent No. 5902293
South African Patent No. 2013/07961
Stay up to date.
Join our mailing list for updates and newsletters on the Usher III Initiative's innovative research and development for Usher 3 Syndrome treatments.